期刊文献+

阿米福汀对甲氨蝶呤诱导细胞凋亡的保护作用 被引量:1

下载PDF
导出
摘要 目的:研究体外培养条件下阿米福汀对甲氨蝶呤诱导正常骨髓单个核细胞凋亡的影响,探讨阿米福汀对甲氨蝶呤导致骨髓抑制的保护作用。方法:将24例特发性血小板减少性紫癜(ITP)患儿分离骨髓单个核细胞,分为空白对照组、甲氨蝶呤组、阿米福汀组、阿米福汀加甲氨蝶呤组,在不同时间点采用形态学观察法,DNA琼脂糖凝胶电泳,流式细胞术检测细胞凋亡的情况。结果:培养8、12、24、48h,甲氨蝶呤组均可见大量的凋亡细胞,阿米福汀加甲氨蝶呤组凋亡细胞明显减少,差异有统计学意义(P〈0.05)。结论:阿米福汀能抑制甲氨蝶呤诱导的正常骨髓单个核细胞凋亡,减少坏死。
出处 《临床血液学杂志》 CAS 2007年第4期237-238,共2页 Journal of Clinical Hematology
  • 相关文献

参考文献7

  • 1SCHUCHTER LM, LUGINBUHL WE, MEROPL NJ. The current status of toxicity protectants in canc er therapy[J]. SeminOncol,1992,19:742--751.
  • 2马晓莉,吴敏媛,胡亚美.婴儿急性白血病的生物学进展[J].临床血液学杂志,2005,18(4):247-250. 被引量:6
  • 3CAPIZZI RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine [J]. Semin Oncol. 1999,26(2suppl 7):3--21.
  • 4SNYDER RD, GRDINA DJ. Further evidence that the radioprotective aminothiol, WR 1065, catalytically inactivates mammalian topoisomerase Ⅱ [J]. Cancer Res, 2000, 60:1186--1188.
  • 5HENSLEY ML, SCHUCHTER LM, LINDLEY C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants[J]. J Clin Oncol, 1999,171 : 3333--3353.
  • 6WASSERMAN T, MACKOWIAK JI, BRIZEL DM, et al. effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer[J]. Int J Radiat Onkol Biol Phys. 2000,48 : 1035-- 1039.
  • 7MAZUR L, CZYZEWSKA A. Immunocytochemical analysis of apoptotic bone marrow cells after treatment of mice with WR-2721 and chemotherapeutics drugs[J]. Folia Histochem Cytobiol, 2001, 39:63-- 66.

二级参考文献10

  • 1Gurney J G, Ross J A, Wall D A, et al. Infant cancer in the U. S: histology-specific incidence and trends,1973 to 1992. J Padiatr Hematol Oncol, 1997, 19:428-432.
  • 2Bresters D, Reus A C, Veerman, et al. Congenital leukemia:: the Dutch experience and review of the literature. Br J Haematol, 2002, 117:513-524.
  • 3Hunger S P, Cleary, Repp R, et al. Backtracking leukemia to birth.: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA, 1997, 94:13950-13954.
  • 4Reaman G H, Sposto R, Sensel M G, et al. Treatment outcome and prognostic factors for infants with acutelymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol, 1999,19:35-42.
  • 5Pui C H, Kalwinsky D K, Schell M J, et al. Acute nonlymphoblastic leukemia in infants:Clinical presentation and outcome. J Clin Oncol, 1988, 6:1008-1013.
  • 6Frankel L S, Ochs J, Shuster J J, et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience. J Pediatric Hematol Oncol, 1997, 19:35-42.
  • 7Dordelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood,1999, 94:1209-1217.
  • 8Lauer S J, Camitta B M, Leventhal B G, et al. Intentive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: a Pediatric Oneology Group pilot study. J Pediatric Hematol Oncol, 1998, 20:229-233.
  • 9Stevens R F, Hann J M, Wheatley K, Gray R G.Marked improvements in outcome with chemotherapy alone in pediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC childhood leukemia working party. Br J Haematol, 1998, 101:130-140.
  • 10Zipursky A, Brown E, Christenen H, et al. Leukemia and/or myleoproliferative syndrome in neonates with Done syndrome. Semin Perinatol, 1997, 21 : 97- 101.

共引文献5

同被引文献56

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部